• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Bristol-Myers CEO Caforio Announces Retirement

Article

Christopher Boerner, chief commercialization officer, set to succeed Caforio in November.

Bristol-Myers Squibb CEO Giovanni Caforio is set to retire, with Chief Commercialization Officer Christopher Boerner taking over the position on November 1. Caforio, who has been at the helm since 2015, will continue in his role as executive chairman. Under his leadership, the company cemented its status as a leading cancer treatment provider, most notably through the $74 billion acquisition of Celgene in 2019.

West Bangal, India - April 20, 2022 : Bristol Myers Squibb logo on phone screen stock image | ©sdx15 | Adobe Stock

Caforio's successor, Christopher Boerner, joined Bristol-Myers in 2015 and has held the role of Chief Commercialization Officer since 2018. He has overseen the company's commercial and medical units and managed key franchises. Read our profile on Christopher Boerner.

The change in leadership comes as Bristol-Myers prepares to lose patent protection on major products like Opdivo and blood thinner Eliquis. The company anticipates new drugs to generate at least $25 billion in sales by 2030.

Reference: Bristol-Myers CEO Giovanni Caforio to Step Down. April 26, 2023 / Wall Street Journal

Related Videos
Related Content